What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality

Claesson-Welsh (2019) What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality EMBO Mol Med (IF: 11.1) 11(8) e10892
Full Text
Full text

Click the PDF icon to view the full text of the paper

Abstract

In this issue of EMBO Molecular Medicine, Uribesalgo and coworkers show that high Apelin expression correlates with poor survival in advanced breast (MMTV-NeuT) and lung (KRASG12D ) murine tumor models as well as in breast and lung cancer in humans. Combining Apelin inhibition (genetically or using an inactive Apelin agonist) with anti-angiogenic therapy using different small molecular weight kinase inhibitors (sunitinib, axitinib) led to marked delay in breast cancer growth in mice. The vasculature in Apelin-targeted cancer showed normalized features including improved perfusion and reduced leakage. These important data provide a strong incentive to target Apelin in human cancer treatment.© 2019 The Author. Published under the terms of the CC BY 4.0 license.

Links

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685083
http://www.ncbi.nlm.nih.gov/pubmed/31318171
http://dx.doi.org/10.15252/emmm.201910892

Similar articles

Tools